$AMRN - Vascepa EVAPORATE primary endpoint was NOT met. Technically, the study failed, although there are extenuating circumstances. Still, this has to be disappointment for those hoping for better.
@adamfeuerstein@matthewherper why? as it turns out the fda never had any concern, the only concern there ever was was planted by people other than the FDA, infact a few panelist today seemed shocked it was even a concer up until today.
People with type 2 diabetes #T2D are 2-3X more likely to develop cardiovascular disease #CVD than those without. Learn more about #T2D and how it may increase the risk of developing other health conditions bit.ly/2vnjll5